Covid-19 roundup: NRx's med gets axed from NIH trial over futility; A new drug for the pandemic enters the clinic
There were more deaths in the treatment group than placebo cohort in an NIH study of NRx Pharmaceuticals’ already-rejected Covid-19 drug, and the data safety …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
